ORMP · Insider Trading
Oramed Pharmaceuticals Inc.
Every open-market purchase and sale reported by ORMP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Joshua Hexter | COO & CBO | Sell | −30,000 | −$135.33K |
| 2026-10-02 | Avraham Gabay | Chief Financial Officer | Sell | −20,000 | −$90.20K |
| 2026-09-25 | Avraham Gabay | Chief Financial Officer | A | +209,291 | — |
| 2026-09-25 | Joshua Hexter | COO & CBO | A | +284,746 | — |
| 2026-09-25 | Miriam Kidron | Chief Scientific Officer | A | +417,416 | — |
| 2026-09-25 | Nadav Kidron | President and CEO | A | +718,262 | — |
| 2026-07-02 | Avraham Gabay | Chief Financial Officer | Sell | −73,360 | −$330.74K |
| 2026-07-02 | Joshua Hexter | COO & CBO | MIXED | −87,000 | −$426.93K |
| 2026-03-18 | Joshua Hexter | COO & CBO | A | +95,889 | — |
| 2026-03-18 | Avraham Gabay | Chief Financial Officer | A | +95,889 | — |
| 2026-03-18 | Nadav Kidron | President and CEO | A | +167,005 | — |
| 2026-03-18 | Miriam Kidron | Chief Scientific Officer | A | +119,558 | — |
| 2026-03-16 | Nadav Kidron | President and CEO | G | −100,000 | — |
| 2026-01-29 | Miriam Kidron | Chief Scientific Officer | M | +19,000 | — |
| 2026-01-29 | Avraham Gabay | Chief Financial Officer | M | +19,000 | — |
| 2026-01-29 | Nadav Kidron | President and CEO | M | +109,000 | — |
| 2026-01-29 | Joshua Hexter | COO & CBO | M | +19,000 | — |
| 2026-01-21 | Miriam Kidron | Chief Scientific Officer | G | −86,166 | — |
| 2026-01-05 | Arie Mayer | Director | A | +34,900 | — |
| 2026-01-05 | Yehuda Reznick | Director | A | +36,250 | — |
| 2026-01-05 | Joshua Hexter | COO & CBO | A | +212,328 | — |
| 2026-01-05 | Miriam Kidron | Chief Scientific Officer | A | +236,331 | — |
| 2026-01-05 | Nadav Kidron | President and CEO | A | +559,640 | — |
| 2026-01-05 | Benjamin Shapiro | Director | A | +33,500 | — |
| 2026-01-02 | Daniel Aghion | Director | A | +36,250 | — |
| 2026-01-02 | Avraham Gabay | Chief Financial Officer | A | +196,216 | — |
| 2025-06-09 | Leonard Sank | Director | A | +36,510 | — |
| 2025-06-09 | Yehuda Reznick | Director | A | +38,370 | — |
| 2025-06-09 | Daniel Aghion | Director | A | +38,371 | — |
| 2025-06-09 | Arie Mayer | Director | A | +36,975 | — |
| 2025-06-09 | Benjamin Shapiro | Director | A | +34,650 | — |
| 2025-02-11 | Nadav Kidron | President and CEO | A | +427,000 | — |
| 2025-02-11 | Joshua Hexter | COO & CBO | A | +126,834 | — |
| 2025-02-11 | Miriam Kidron | Chief Scientific Officer | A | +192,667 | — |
| 2025-02-11 | Avraham Gabay | Chief Financial Officer | A | +76,000 | — |
| 2025-01-06 | Miriam Kidron | Chief Scientific Officer | A | +207,000 | — |
| 2025-01-06 | Joshua Hexter | COO & CBO | A | +194,500 | — |
| 2025-01-06 | Avraham Gabay | Chief Financial Officer | A | +188,000 | — |
| 2025-01-06 | Nadav Kidron | President and CEO | A | +433,500 | — |
| 2024-11-08 | Avraham Gabay | Chief Financial Officer | A | +30,000 | — |
| 2024-11-08 | Miriam Kidron | Chief Scientific Officer | A | +30,000 | — |
| 2024-11-08 | Joshua Hexter | COO & CBO | A | +30,000 | — |
| 2024-11-08 | Nadav Kidron | President and CEO | A | +45,000 | — |
| 2024-06-21 | Avraham Gabay | Chief Financial Officer | A | +140,040 | — |
| 2024-06-10 | Yehuda Reznick | Director | A | +760 | — |
| 2024-04-18 | Yehuda Reznick | Director | A | +29,800 | — |
| 2024-01-30 | Daniel Aghion | Director | A | +3,750 | — |
| 2024-01-08 | David Silberman | Chief Financial Officer | A | +136,500 | — |
| 2024-01-08 | Joshua Hexter | COO & CBO | A | +180,500 | — |
| 2024-01-08 | Nadav Kidron | President and CEO | A | +329,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Nadav Kidron | President and CEO | 3,897,740 | $16.02M |
| Benjamin Shapiro | Director | 2,019,720 | $8.30M |
| Miriam Kidron | Chief Scientific Officer | 1,550,554 | $6.37M |
| Joshua Hexter | COO & CBO | 1,328,130 | $5.46M |
| Avraham Gabay | Chief Financial Officer | 861,076 | $3.54M |
| Leonard Sank | Director | 266,910 | $1.10M |
| Arie Mayer | Director | 168,009 | $690.52K |
| Daniel Aghion | Director | 107,191 | $440.56K |
| Yehuda Reznick | Director | 105,180 | $432.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ORMP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.